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MISCELLANEOUS
Prevention of Urinary Tract Infection with Oximacro®, A Cranberry Extract with a High Content of 
A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study
Purpose: Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. Cran-
berry juices and extracts have been used for UTI prevention due to their content of bioactive proanthocyanidins 
(PACs), particularly of the A type (PAC-A). Controversial clinical results obtained with cranberry are often due 
to a lack of precise determination and authentication of the PAC-A content. This study used Oximacro® (Bios-
fered S.r.l., Turin, Italy), a cranberry extract with a high content of PAC-A, to prevent UTIs in female and male 
volunteers.
Materials and Methods: The Oximacro® PACs content was assayed using the Brunswick Laboratories 4-di-
methylaminocinnamaldehyde (BL-DMAC) method, and the dimer and trimer PACs-A and PACs-B percentages 
were determined via high-performance liquid chromatography/electrospray ionization tandem mass spectrometry 
(HPLC/ESI-MS/MS). A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 
51 years) was divided into two groups. The experimental group received 1 capsule containing Oximacro® (36 mg 
PACs-A) twice per day (morning and evening) for 7 days, and the placebo group was given the same number of 
capsules with no PACs.
Results: Analysis of Oximacro® revealed a high total PAC content (372.34 mg/g ± 2.3) and a high percentage of 
PAC-A dimers and trimers (86.72% ± 1.65). After 7 days of Oximacro® administration, a significant difference 
was found between the placebo and Oximacro® groups for both females (Mann-Whitney U-test = 875; P < .001; n 
= 60) and males (Mann-Whitney U-test = 24; P = .016; n = 10). When the female and male age ranges were ana-
lysed separately, the female age range 31-35 showed only slightly significant differences between the placebo and 
Oximacro® groups (Mann-Whitney U-test = 20.5; P = .095; n = 10), whereas all other female age ranges showed 
highly significant differences between the placebo and Oximacro® groups (Mann-Whitney U-test = 25; P = .008; 
n = 10). Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < 
.001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak 
Adjusted P < .001, Bonferroni Adjusted P < .001).
Conclusion: Careful determination of the total PAC content using the BL-DMAC method and the authentication 
of PACs-A with mass spectrometry in cranberry extracts are necessary to prepare effective doses for UTI preven-
tion. A dose of 112 mg Oximacro® containing 36 mg PACs-A was found to be effective in preventing UTIs when 
used twice per day for 7 days.
Keywords: urinary tract infections; prevention & control; plant extracts; pharmacology; humans; urinalysis; ther-
apeutic use; Vaccinium macrocarpon.
INTRODUCTION
Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. 
Approximately 13 million women in the United States 
and approximately 150 million people worldwide de-
velop UTIs each year, with societal costs of approxi-
mately 3.5 billion USD per year in the USA alone.(1) 
An estimated 40% of women develop at least one UTI 
during their lifetimes.(2) UTIs refer to the presence of a 
certain threshold number of bacteria in the urine (usu-
ally > 105/mL) and consist of cystitis (or lower UTIs, 
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with bacteria in the bladder), urethral syndrome and 
pyelonephritis (or upper UTIs, with infection of the 
kidneys).(3) Bacterial cystitis (also called acute cystitis) 
can occur in women and men, and the signs and symp-
toms include dysuria (pain on passing urine), frequen-
cy, cloudy urine, and occasionally haematuria (blood in 
the urine); bacterial cystitis is also often associated with 
pyuria (urine white cell count > 104/mL). Some people 
also develop recurrent UTIs with an average of two to 
three episodes/year.(4) 
The berries of cranberry (Vaccinium macrocarpon Ai-
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ton) have been used for hundreds of years as a remedy 
for diseases of the urinary tract and have attracted atten-
tion due to their potential health benefits.(5,6) The benefi-
cial mechanism of cranberry was historically thought to 
be due to the fruit’s acids causing a bacteriostatic effect 
in the urine. However, recently, a group of proantho-
cyanidins (PACs) with A-type linkages (PAC-A) was 
isolated from cranberries and shown to exhibit bacterial 
antiadhesion activity against both antibiotic-suscepti-
ble and -resistant strains of uropathogenic P-fimbriated 
Escherichia coli (E. coli) bacteria, including multid-
rug-resistant E. coli.(7-10) Central in the efficacy of cran-
berry extract/juice is the determination of the optimum 
dose of PAC-A, which is an essential requirement in 
establishing botanical supplements as viable supports 
to conventional therapies.(11) Recent studies have re-
vealed that cranberry extract regimens containing 72 
mg PACs produce significant bacterial antiadhesion ac-
tivity in human urine.(2,10) Clearly, the dose of bioavaila-
ble PAC-A is central to the issue of cranberry efficacy. 
Currently, four methods are used to evaluate the con-
tent of cranberry PACs; two methods are based on the 
depolymerisation of PACs (e.g., the hydrochloric acid 
butanol method known as Bates-Smith and the Europe-
an Pharmacopoeia method), and two are colorimetric 
methods (a ultraviolet-visible [UV-VIS] spectrophoto-
metric method based on Prussian-blue or Folin-Ciocal-
teu reagents and the Brunswick Laboratories 4-dimeth-
ylaminocinnamaldehyde [BL-DMAC] method). The 
BL-DMAC colorimetric method (an aldehyde conden-
sation of 4-dimethylaminocinnamaldehyde) appears to 
be more accurate than the other methods and has been 
successfully used to quantify cranberry PACs.(12) In par-
ticular, the BL-DMAC method is less likely to be sub-
ject to interference from cranberry components, such as 
anthocyanins, because the reaction is read at 640 nm. 
However, the BL-DMAC method, although specific for 
PAC quantification, is not able to distinguish between 
A- and B-type PACs;(13) therefore, analytical meth-
ods, such as high-performance liquid chromatography 
(HPLC) coupled to mass spectrometry or fluorescence 
detectors, are necessary for PACs-A authentication.(14) 
Oximacro® is a cranberry extract with the highest con-
tent of PACs (according to the BL-DMAC method) and 
the highest percentages of PAC-A dimers and trimers 
(based on Liquid chromatography [LC]/mass spectrom-
etry [MS] identification) available on the market. Here, 
we report on the chemical analysis of the PAC content 
of Oximacro® and its action in preventing UTIs based 
on a pre-clinical double-blind controlled study on male 
and female volunteers.
MATERIALS AND METHODS
Reagents
Oximacro®, a cranberry (Vaccinium macrocarpon 
Aiton) extract, was provided by Biosfered S.r.l. (Tu-
rin, Italy) and produced from cranberries as a reddish 
powder with a total PAC content > 360 mg/g (Lot # 
CR0104-PD01). The CoA of the product is available at 
the company web site (http://www.biosfered.com). Ex-
trasynthese (Lyon, France) provided pure standards of 
PAC-A and PAC-B. The pure chemicals were dissolved 
in 96% v/v ethanol (Sigma-Aldrich, Carlsbad, USA) at 
a final concentration of 100 µg/mL. Aliquots of stock 
solutions were stored in 1.5-mL HPLC vials at -80°C 
Figure 1. Spectral analysis of the BL-DMAC reaction of PAC-A (black line) and PAC-B (red line). When tested at the same concentration (20 µg mL-1), 
PAC-B showed a higher absorbance (at 640 nm) than PAC-A.
Abbreviations: PAC, proanthocyanidins; BL-DAMC, Brunswick Laboratories 4-dimethylaminocinnamaldehyde.
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until use. The chemical purity and integrity of standard 
compounds was assessed (see below) prior to use.
Determination of the Total PAC Content with the 
BL-DMAC Method
The BL-DMAC assay was performed according to the 
method of Prior and colleagues(12) with minor modifica-
tions. Extraction buffer was composed of acidified 75% 
v/v acetone (VWR International, Milan) with 0.5% v/v 
acetic acid (Sigma-Aldrich, Carlsbad, USA). Acidified 
ethanol was composed of 72% v/v ethanol and hydro-
chloric acid (Sigma-Aldrich, Carlsbad, USA) at a final 
concentration of 1.52 M. DMAC solution was com-
posed of 0.1% w/v 4-(dimethylamino)-cinnamaldehyde 
(DMAC) (Sigma-Aldrich, USA) in acidified ethanol; 
this solution was freshly prepared prior to the assay. 
Briefly, Oximacro® (20-30 mg) was dissolved in 5 mL 
of extraction buffer. The powder was extracted in an 
ultrasonic bath at room temperature for 20 min and then 
shaken with an orbital shaker for 1 h. Samples were 
centrifuged at 5,000 g for 10 min and then diluted in the 
extraction buffer prior to spectrophotometric assay. The 
colorimetric reaction was performed by mixing 0.84 
mL DMAC solution and 0.28 mL of a diluted sample in 
a 1.5-mL plastic cuvette. The total PACs were quanti-
fied via an external calibration curve made with a pure 
PAC-A standard. The reaction kinetics of both PAC 
standards (PAC-A and PAC-B) were determined using 
a time-course BL-DMAC assay. A concentration of 20 
µg/mL was tested for both standards. The reaction was 
incubated in the dark from 1 to 25 min to assess the dy-
namics of the DMAC reaction, and the absorbance was 
read at 640 nm (Cary60, Agilent-Technologies, Califor-
nia, USA) against a blank composed of acidified ethanol 
and DMAC solution. The quantification was performed 
in triplicate within the linear range of calibration curves 
(5-30 µg/mL). Oximacro® was then assayed exactly 
at 20 min, which corresponds to the maximum absorb-
ance value for PAC-A. To test the reactivity of PAC-A 
and PAC-B to DMAC, 20 µg/mL solutions of PAC-A 
and PAC-B were tested with increasing percentages of 
PAC-B (0, 25, 50, 75 and 100%). The final concentra-
tion of the tested mixtures was always 20 µg/mL. The 
absorption spectra were recorded between 350 and 800 
nm, exactly 20 min after the beginning of the DMAC 
colorimetric assay. 
Authentication of the PAC-A Content in Oximacro®
PAC-A and PAC-B authentication of Oximacro® were 
obtained via liquid chromatography (1200 HPLC, Ag-
ilent Technologies, California, USA) equipped with a 
reverse phase (RP) C18 Kinetex (2.6 µm, 100 × 3.0 
mm, Phenomenex, California, USA) column. The bi-
nary solvent system was A) MilliQ H2O (Millipore, 
Billerica, Massachusetts, USA) with 0.1% v/v of for-
mic acid and B) acetonitrile (VWR International, USA) 
with 0.1% v/v of formic acid. Chromatographic separa-
tion was carried out at constant flow rate (200 µL/min) 
using the following conditions: linear gradient from 5% 
to 30% of B in 10 min and isocratic elution for 5 min 
and 20 min at 50% of B and 24 min at 90% of B at 
24 min. The initial mobile phase was re-established for 
10 min prior to the next injection. Tandem mass spec-
trometry analyses were performed with a 6330 Series 
Ion Trap LC-MS System (Agilent Technologies, Cali-
fornia, USA) equipped with an electrospray ionization 
Figure 2. Time-course of the BL-DMAC reaction of 20 µg mL-1 PAC-A and PAC-B. When used at the same concentration, PAC-B (dotted line) reacts 
more rapidly and with a higher absorbance with respect to PAC-A (solid line). Metric bars represent standard deviation.
Abbreviations: PAC, proanthocyanidins; BL-DAMC, Brunswick Laboratories 4-dimethylaminocinnamaldehyde.
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source (ESI) operating in negative mode. The identifi-
cation of PAC-A (dimers and trimers) was performed 
via multiple reaction monitoring (MRM) by monitoring 
the following parental ions [M-H]-: 575, 577, 861, 863 
and 865 m/z.
Study Population and Inclusion and Exclusion 
Criteria
To assess the effect of Oximacro®, we recruited partic-
ipants from a population of volunteers (10 male and 60 
female) involved in studies performed by the Farmacia 
Antoniana (San Gillio, Italy) under the supervision of 
medical doctors. Informed consent was obtained. The 
inclusion criteria included any woman or man at least 
18 years of age to over 51 years of age with at least 2 
culture-documented symptomatic UTIs in the calendar 
year prior to recruitment. The choice of volunteers was 
completely balanced, and volunteers with known ana-
tomical abnormalities (posterior urethral valves, neuro-
genic bladder, or any urinary obstruction) were exclud-
ed from this study. Urinary infection was defined as a 
positive culture of a midstream sample with a uropath-
ogenic bacterium at 105 colony forming unit (CFU)/mL 
in symptomatic volunteers with no more than two spe-
cies of organisms present. We accepted lower counts 
(104 CFU/mL) if the volunteer had typical symptoms 
of UTI and positive white blood cells and/or nitrites on 
urine analyses. Specific symptoms and signs includ-
ed pain before, during, or after micturition; increased 
frequency of micturition; pain in abdomen; haema-
turia; foul smell; and signs of common sickness (fever 
> 37.9°C or 1.5°C above baseline, temperature, chills, 
nausea, and vomiting). Nonspecific symptoms were 
considered anorexia, fatigue and reduced mobility, and 
signs of delirium (e.g., confusion and deterioration in 
mental or functional status). Asymptomatic bacteriuria 
was not considered an end point. After explaining the 
study and obtaining consent, patients were assigned to 
the placebo group or experimental randomized groups. 
The randomization was concealed. 
Oximacro® Administration and Dosage
Capsules contained 500 mg of the product [112 mg 
Oximacro® (equivalent to 36% PAC-A), 383 mg mi-
Percentage of a 20 µg mL-1 PAC-A Solution Percentage of a 20 µg mL-1 PAC-B Solution  Total PACs, expressed as µg mL1  (± standard deviation)
100    0    20.49a (± 0.65)
75    25    22.65b (± 1.48)
50    50    25.49c (± 2.55)
25    75    28.18d (± 2.48)
0    100    31.29e (± 2.19)
Abbreviations: PAC, proanthocyanidins.
Table 1. Comparative analysis of total PACs content based on a PAC-A calibration curve with an increasing percentage of PAC-B (± standard error; n 
= 3). In the same column, different letters indicate significant (P < .05) differences.
Figure 3. BL-DMAC spectral analysis of a 20 µg mL-1 solution of PAC-A and PAC-B used at increasing PAC-B concentrations. Increasing PAC-B 
causes an absorbance increase at 640 nm.
Abbreviations: PAC, proanthocyanidins; BL-DAMC, Brunswick Laboratories 4-dimethylaminocinnamaldehyde; Abs, absorbency.
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crocrystalline cellulose and 5 mg magnesium stearate]. 
The placebo was indistinguishable in colour, taste, and 
appearance, consisting of all elements above without 
Oximacro® and coloured with azorubine. The experi-
mental group (5 males and 30 females) received 1 cap-
sule containing 36% PAC-A twice per day (morning 
and evening) for 7 days, and the placebo group (5 males 
and 30 females) was given the same number of capsules 
with no PACs. A score (from 0, representing no effect, 
to 10, representing a maximum effect of Oximacro® in 
preventing UTI) was recorded for all volunteers. To ob-
tain linearity, the logarithm of the scores (Ln scores) 
was used. The dose was calculated based on previous 
clinical trials.(10) The administration was performed for 
7 days; during this time, the volunteers were followed 
with alternating visits and telephone calls every 2 days. 
At the end of the treatment period, a urine sample was 
sent for urine analysis and urine culture. To avoid con-
tamination, the volunteers were asked to not use antibi-
otics or any other cranberry products for the duration of 
the study, with the exception of the placebo group, in 
which volunteers were asked to immediately report on 
symptoms. In the latter case, they were asked to use the 
antibiotic prescribed by the medical doctor and to in-
terrupt the placebo administration. The attending urolo-
gists, outcome assessor and statistician were all blinded 
to the group allocations. 
Statistical Analysis
We performed Fisher’s exact tests on the tabulated fre-
quencies to assess the effect of the treatments. Kolmog-
orov–Smirnov tests were used to assess the distribution 
type for the continuous variable, i.e., the average value 
of the score. The data were log-transformed. Accord-
ingly, a non-parametric analysis of variance was used 
to assess the differences in the Oximacro® and place-
bo groups according to the sex and age categories. The 
median, quartile, maximum and minimum score values 
are represented in boxplots; outliers are represented by 
asterisks. A binary logistic regression was performed to 
test the independent effects of age and sex on Oximac-
ro® outcomes. All statistical analyses were performed 
using Statistical Package for the Social Science (SPSS 
Inc, Chicago, Illinois, USA) version 22.0. The inten-
Table 2. Volunteers baseline characteristics.
Variables    Experimental Group, Oximacro® Administration, n = 35 Placebo Group, n = 35
Demographics
Females, no (%)    30 (85.7)    30 (85.7)
Males, no (%)    5 (14.3)    5 (14.3)
Median age (range)    38 (19-61)    38 (19-63)
Age range  
 19-24    5 (F)    5 (F)
 25-30    5 (F)    5 (F)
 31-35    5 (F)    5 (F)
 36-40    5 (F)    5 (F)
 41-50    5 (F)    5 (F)
 > 51    5 (F), 5 (M)    5 (F), 5 (M)
Baseline characteristics
Acute UTI, no (%)    35 (100)    35 (100)
Bladder and bowel dysfunction, no (%)   35 (100)    35 (100)
Average UTIs in years prior to treatment   2.5    2.6
Number of capsules (days)    2 (7)    2 (7)
Volunteers not completing the study, no (%)  6 (17)    15 (43)
 Females, no (%)   6 (17)    13 (43)
 Males, no (%)    1 (20)    3 (60)
Abbreviations: M, male; F, female; UTI, urinary tract infections.
Variables  Placebo  Oximacro®
Not recovered  35  7
Recovered  0  28
Fisher's Exact Test: P < .001
 Table 3. Contingency table.
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tion-to-treat principle was followed.
RESULTS
One of the key points in UTI prevention is the assess-
ment of the content of bioactive PACs-A, which are 
contained in the capsule. Total PAC content can be 
quantitated using various methods, among which the 
BL-DMAC method is generally recognised as the most 
accurate.(12,13) However, the BL-DMAC assay is sensi-
tive to the presence of both PACs-A and PACs-B. When 
we measured the standards of PAC-A and PAC-B using 
the BL-DMAC method, we found that the same amount 
of PAC reacted differently with various absorbance 
spectra (Figure 1). In particular, a higher absorbance 
(at 640 nm) was found for PAC-B than PAC-A (Figure 
1).
A time-course experiment was then performed by meas-
uring the BL-DMAC reaction of 20 µg/mL PAC-A and 
PAC-B. PAC-B reached maximum absorbance after 11 
min, whereas PAC-A showed a maximum absorbance at 
20 min (Figure 2). PAC-A and PAC-B purity standards 
were analysed to assess purity and integrity; the results 
showed that the purity was identical to that declared by 
the supplier. To determine whether a mixture of PAC-A 
and PAC-B with increasing percentages of the two 
PACs could result in differing PAC quantifications, we 
assayed the BL-DMAC of the mixtures and found that 
the presence of PAC-B increased the absorbance values 
measured at 640 nm (Figure 3). Finally, we calculated 
the total amount of PACs based on a calibration curve 
prepared with a PAC-A standard using mixtures with 
increasing percentages of PAC-B and decreasing per-
centages of PAC-A at a final concentration of 20 µg/
mL, as calculated using the gravimetric method. Table 
1 shows that the total amount of PACs increased with 
increasing PAC-B content despite a constant amount of 
total PACs used.
These results indicate that the BL-DMAC method is 
time-sensitive (in our analyses, the best timing for the 
PAC-A reaction was 20 min) and that shorter reaction 
times may lead to overestimating the total PAC content. 
The latter result may occur in cases of high amounts of 
PAC-B. Furthermore, our results confirm that the BL-
DMAC method does not distinguish between PAC-A 
Figure 4. HPLC-ESI-MS/MS analysis of Oximacro®. A) HPLC-ESI-MS/
MS chromatogram of dimers and trimers of PAC-A and PAC-B. The mass 
spectrometry analysis performed in MRM mode shows the presence of 
PAC-A dimers (black line) and trimers (blue line) and PAC-B dimers (red 
line). B) MS2 spectra in negative mode of a typical PAC-B dimer ([M-H]-
1 575 m/z). C) MS2 spectra in negative mode of a typical PAC-A dimer 
([M-H]-1 577 m/z). 
Abbreviations: PAC, proanthocyanidins; HPLC-ESI-MS/MS, high-per-
formance liquid chromatography/electrospray ionization tandem mass 
spectrometry; MRM, Multiple Reaction Monitoring.
Figure 5. Boxplot representing the logarithm of the scores of the place-
bo and Oximacro® groups in both females and males volunteers. Females 
differences between placebo and Oximacro®: Mann-Whitney = 875; 
P < .001; n = 60; males differences between placebo and Oximacro®: 
Mann-Whitney = 24; P = .016; n = 10.
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and PAC-B and that even when a calibration curve is 
obtained with PAC-A, an increased amount of PAC-B 
eventually increases the absorbance at 640 nm, thereby 
affecting the total PAC quantification. Therefore, a high 
PAC value obtained with the BL-DMAC method does 
not necessarily indicate a high amount of PAC-A even 
though a calibration curve is calculated with a PAC-A 
standard.
Having assessed the best timing for PAC determina-
tion, we next measured the total amount of Oximac-
ro® PACs. The BL-DMAC method showed a total of 
372.34 mg/g (± 2.3) PACs, in line with that declared 
by the producer. To our knowledge, and based on the 
BL-DMAC method, this is the highest amount of PACs 
reported for a cranberry extract that is currently on the 
market.
The bioactivity of cranberry against UTI is dependent 
on the PAC-A content(9,15,16) (particularly dimers and 
trimers);(17-19) thus, we analysed Oximacro® via HPLC 
followed by electrospray ionization (EI) and tandem 
mass spectrometry (ESI-MS/MS). Oximacro® was 
primarily composed of PAC-A dimers followed by a 
lower amount of PAC-A trimers (Figures 4a and 4c). 
The total percentages of PAC-A and PAC-B based on 
HPLC-ESI-MS/MS were 86.72% (± 1.65) and 13.99% 
(± 1.03), respectively (Figures 4a-c). The percentage 
of other PAC polymers was below the threshold of de-
tection.
Considering the total PACs (calculated using the BL-
DMAC method) and the percentage of PAC-A dimers 
and trimers, Oximacro® showed a total PAC-A content 
of 322.89 mg/g (± 1.58). Therefore, 112 mg of Oxi-
macro® contains 360 mg/g PAC-A. Following the as-
sessment and authentication of the PAC-A content of 
Oximacro®, we prepared capsules containing 112 mg 
of Oximacro® (which corresponds to 36% PAC-A) and 
placebo capsules. In all volunteers, the infection prior 
to recruitment was due to E. coli in 85%, other enteric 
Gram-negative bacilli in 10%, and more than 1 type of 
bacteria in 5% of the volunteers. Table 2 shows the vol-
unteers’ demographic and baseline characteristics.
Reasons for dropout in the experimental group included 
relocation (1), feeling better prior to the end of treat-
ment  (4), contrary advice from a family doctor (1), 
and a family perception of Oximacro® ineffectiveness 
(1). Reasons for dropout in the placebo group included 
acute pain (12), contrary advice from a family doctor 
(2), and a family perception of Oximacro® ineffective-
ness (1). The median follow-up time in both groups was 
4 weeks.
The mean capsule intake was 97% (95% CI: 96.6–
97.6%) and was similar between the experimental and 
placebo groups. After 7 days of Oximacro® and place-
bo administration, a contingency table was calculated 
based on recovered vs. not recovered volunteers (Table 
3); this table showed a significant difference (Fisher’s 
exact test: P < .001) between the Oximacro® and pla-
cebo groups. A general Mann-Whitney U-test test fur-
ther showed a highly significant difference between the 
placebo and Oximacro® groups (1191; P < .001; n = 
70), with most of the placebo group unable to recover 
from UTI. Eventually, all placebo volunteers had to be 
treated with antibiotics (Monuril®, trometamol salt of 
fosfomycin) to reduce pain. Figure 5 shows the boxplot 
of female and male scores; a significant difference was 
found between the placebo and Oximacro® groups for 
both females (Mann-Whitney U-test = 875; P < .001; n 
= 60) and males (Mann-Whitney U-test = 24; P = .016; 
n = 10). Significant differences were also found when 
the age ranges were analysed. In particular, between the 
placebo and Oximacro® groups, the female age ranges 
of 19-24, 25-30, 36-40, 41-50 and over 51 years showed 
Figure 6. Boxplot representing the logarithm of the scores  of the placebo and Oximacro® groups in both females (left panel) and males (right panel) 
volunteers according to the age range. Left panel, females age range-based (19-24, 25-30, 36-40, 41-50 and > 51 years) differences between placebo and 
Oximacro®: for each age range, Mann-Whitney = 25; P = .008; n = 10; differences between placebo and Oximacro® for the female age range of 31-3 
years: Mann-Whitney = 20.5; P = .095; n = 10. Right panel, differences between placebo and Oximacro® for the male age range over 51: Mann-Whitney 
= 24; P = .016; n = 10.
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highly significant differences (for each age range: 
Mann-Whitney U-test = 25; P = .008; n = 10); the age 
range from 31-35 years showed barely significant dif-
ferences (Mann-Whitney U-test = 20.5; P = .095; n = 
10) (Figure 6 left panel). For males, the only age range 
(over 51) showed a significant difference between the 
placebo and Oximacro® groups as reported above (Fig-
ure 6 right panel). Finally, considering the CFU/mL 
counts from the urocultures, a significant difference (P 
< .001) was found in the comparison between the ex-
perimental group and the placebo group (SD difference 
= 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < 
.001, Bonferroni Adjusted P < .001). 
Overall, these results show that the administration of 
Oximacro® significantly ameliorated UTI in the treat-
ment group. When a multivariate binary logistic regres-
sion was performed to examine the independent effect 
of Oximacro® on healing (dependent variable) based on 
sex and age (covariates), no significant effect (P > .900) 
for categorical variables was found for the treatment 
outcomes (data not shown).
DISCUSSION
The efficacy of cranberry in preventing UTIs remains 
controversial primarily due to contrasting results in-
dicating either a nonsignificant effect (as in the case 
of cranberry juice drinking)(20-23) or an extended dura-
tion therapy requirement (e.g., 12 months of drinking 
cranberry juice).(24) In individuals with recurrent UTIs, 
low-dose antibiotic prophylaxis for several months is 
usually recommended.(25) However, extended use of 
antibiotics may lead to the development of antibiotic 
resistance. Indeed, several E. coli isolates are resistant 
to antimicrobial treatment, and the interest in non-anti-
biotic methods for the prevention of UTIs is growing.(26) 
If the dosage of non-antibiotic methods is not standard-
ized, the cost/effect ratio may be higher than antibiotic 
treatment, as recently shown with a cranberry prophy-
laxis regimen for preventing UTIs in which the PAC-A 
treatment was far below (18.2 mg/day) the recommend-
ed dosage (72 mg). In this case, the cranberry treatment 
was less effective and more expensive than (dominated 
by) trimethoprim-sulfamethoxazole prophylaxis.(27) The 
use of concentrated cranberry extract with a high PAC 
content has been successfully proven to prevent UTIs 
in women who are subject to recurrent infections.(7,9,10, 
18,28-31) Despite these positive results, one of the major 
concerns is the quantification of PACs-A, which are the 
only bioactive compounds thus far demonstrated to ex-
ert a significant uropathogenic bacterial anti-adhesion 
effect.(9,19) A recent survey on the PAC content of some 
cranberry extract products via both BL-DMAC and 
HPLC found that BL-DMAC values for the PAC con-
tent per unit were below those declared by the manufac-
turers. In particular, some cranberry extract medicinal 
products showed a A-type PAC content so low that they 
would have no chance of providing health benefits;(32) 
the availability of these extracts was likely the result 
of overestimation of the PAC content provided by the 
Bates-Smith and the European Pharmacopoeia meth-
ods. On the one hand, these methods grant a high per-
centage value; on the other hand, by overestimating the 
real PAC content, these methods limit the health bene-
fits of cranberry extracts. The cranberry industry is cur-
rently using BL-DMAC as a standard method;(13) how-
ever, the BL-DMAC method is unable to discriminate 
between A- and B-type PACs.(13) It is thus important to 
combine accurate timing and the kinetics of the method 
with the HPLC-MS authentication of PAC types. The 
results of this work show that the presence of PAC-B in 
cranberry extract can overestimate the total PAC con-
tent based on a PAC-A calibration curve. For instance, 
a cranberry extract with a high percentage of PAC-B (as 
is typical in some cranberry cultivars) may yield a high 
total PAC value with the BL-DMAC method despite a 
PAC-A standard calibration curve. Furthermore, in our 
conditions (see the Materials and Methods), 20 min of 
reaction were required for an accurate PAC-A deter-
mination (complete saturation of the reaction). There-
fore, the standardization of PACs using the BL-DMAC 
method and the authentication of PAC-A with LC-MS 
is a prerequisite in preparing cranberry dosages for the 
prevention of UTIs. 
Our results showed that the cranberry extract Oximac-
ro® contains a high total PAC content and a high per-
centage of bioactive PAC-A dimers and trimers. When 
administered to volunteers, the extract was particularly 
suitable for UTI prevention, and 112 mg Oximacro® 
(equivalent of 36 mg PACs-A) twice per day for 7 days 
was significantly effective in reducing the total urobac-
terial CFU counts in both the female and male groups 
with respect to placebo. The age ranges were unaffected 
by treatment with the sole exception of the 31-35 year 
age range in the female group. This group did not differ 
in baseline characteristics with respect to the other age 
groups; thus, the reason for the reduced effect of Oxi-
macro® in this group requires further investigation. A 
literature search on age-related responses to cranberry 
treatment did not provide any reported cases, although 
further studies will focus on this aspect.
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The results of this work are in agreement with previous 
randomized, double-blind versus placebo multicentre 
studies examining the effects of 72 mg of PAC-stand-
ardized cranberry.(2,10,13) Furthermore, our results show 
that 72 mg PAC-A is highly effective, and we suggest 
the use of dosages based on PACs-A instead of the total 
PACs in UTI treatment. Due to the impossibility of BL-
DMAC in discriminating between PAC-A and PAC-B, 
the sole total PACs quantification may not be sufficient 
in providing the required amount of PAC-A needed to 
significantly inhibit UTIs. Further studies will assess 
the recurrence of UTIs in Oximacro®-supplemented 
volunteers.
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